Lyell Immunopharma Q4 net loss $8.4M, revenue $48.4M; cash $710.3M

Lyell Immunopharma, Inc.

2022-FY EPS reported -$0.74 revenue$84,683,000

Q4 2022 net loss $8.4M (vs $83.7M Q4 2021); full year net loss $183.1M (vs $250.2M).
Revenue $48.4M in Q4 2022, up from $2.8M in Q4 2021, driven by GSK collaboration deferred revenue.
Cash, cash equivalents and marketable securities $710.3M as of Dec 31, 2022; cash runway into 2026.
Phase 1 trials ongoing for LYL797 (ROR1 CAR T) and LYL845 (TIL); initial data expected in 2024.
Lynn Seely named President and CEO in Dec 2022; Rahsaan Thompson CLO; Gary Lee CSO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the year ended December 31, 2022 results: net income $183.1 million.

Period: the year ended December 31, 2022
Net income: $183.1 million
Result: reported results

Exact text from the filing

Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.4 million.

Period: the fourth quarter ended December 31, 2022
Net income: $8.4 million
Result: reported results

Exact text from the filing

Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-005554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.